Katherine C. Verbist
Research Subjects
Katherine C. Verbist has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Douglas R. Green
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, USA
6 shared publications Christopher P. Dillon
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
3 shared publications- Kimberly D. Klonowski
Department of Cellular Biology, University of Georgia , Athens, GA 30602
3 shared publications Mary B. Field
Department of Cellular Biology, University of Georgia, Athens, Georgia, United States of America
3 shared publicationsPaige Tedrick
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
3 shared publicationsRuoning Wang
Center for Childhood Cancer and Blood Disease, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio 43205, USA
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 11 July 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (2) , 147-159
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an often-fatal disorder characterized by the overactivation of T cells and macrophages that excessively produce proinflammatory cytokines, including interferon-γ (IFN-γ). Previously, we reported that the JAK inhibitor ruxolitinib dampens T-cell activation and lessens inflammation in a model of HLH in which perforin-deficient (Prf1−/−) mice are infected with lymphocytic choriomeningitis virus (LCMV). Ruxolitinib inhibits signaling downstream of IFN-γ, as well as several other JAK-dependent cytokines. As a consequence, it remained unclear whether ruxolitinib was exerting its beneficial effects in HLH by inhibiting IFN-γ signaling or by targeting signaling initiated by other proinflammatory cytokines. To address this question, we compared the effects of ruxolitinib with those obtained using an IFN-γ–neutralizing antibody (αIFN-γ) in 2 murine HLH models. In both models, ruxolitinib and αIFN-γ reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-γ–dependent manner to reverse this HLH manifestation. In contrast, the number and activation status of T cells and neutrophils, as well as their infiltration into tissues, were significantly reduced following treatment with ruxolitinib, but they remained unchanged or were increased following treatment with αIFN-γ. Notably, despite discontinuation of ruxolitinib, LCMV-infected Prf1−/− mice exhibited enhanced survival compared with mice in which αIFN-γ was discontinued. This protective effect could be mimicked by transient treatment with αIFN-γ and a neutrophil-depleting antibody. Thus, ruxolitinib operates through IFN-γ–dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.
- 11 July 2019
- Published by American Society of Hematology in Blood
- Vol. 134 (2) , 147-159
Top Cited PapersOpen AccessMechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is an often-fatal disorder characterized by the overactivation of T cells and macrophages that excessively produce proinflammatory cytokines, including interferon-γ (IFN-γ). Previously, we reported that the JAK inhibitor ruxolitinib dampens T-cell activation and lessens inflammation in a model of HLH in which perforin-deficient (Prf1−/−) mice are infected with lymphocytic choriomeningitis virus (LCMV). Ruxolitinib inhibits signaling downstream of IFN-γ, as well as several other JAK-dependent cytokines. As a consequence, it remained unclear whether ruxolitinib was exerting its beneficial effects in HLH by inhibiting IFN-γ signaling or by targeting signaling initiated by other proinflammatory cytokines. To address this question, we compared the effects of ruxolitinib with those obtained using an IFN-γ–neutralizing antibody (αIFN-γ) in 2 murine HLH models. In both models, ruxolitinib and αIFN-γ reduced inflammation-associated anemia, indicating that ruxolitinib operates in an IFN-γ–dependent manner to reverse this HLH manifestation. In contrast, the number and activation status of T cells and neutrophils, as well as their infiltration into tissues, were significantly reduced following treatment with ruxolitinib, but they remained unchanged or were increased following treatment with αIFN-γ. Notably, despite discontinuation of ruxolitinib, LCMV-infected Prf1−/− mice exhibited enhanced survival compared with mice in which αIFN-γ was discontinued. This protective effect could be mimicked by transient treatment with αIFN-γ and a neutrophil-depleting antibody. Thus, ruxolitinib operates through IFN-γ–dependent and -independent mechanisms to dampen HLH by targeting the deleterious effects of T cells and neutrophils, with the latter representing an unappreciated and understudied cell type that contributes to HLH pathogenesis.
- Top Cited Papers
- 1 May 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (5) , 937-948.e8
Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia
- 1 May 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (5) , 937-948.e8
Top Cited PapersGermline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia
- 1 July 2016
- Published by Elsevier in Cell Host & Microbe
- Vol. 20 (1) , 13-24
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus
- 1 July 2016
- Published by Elsevier in Cell Host & Microbe
- Vol. 20 (1) , 13-24
RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus
- Open Access
- 11 April 2016
- Published by Springer Nature in Nature
- Vol. 532 (7599) , 389-393
Metabolic maintenance of cell asymmetry following division in activated T lymphocytes
The asymmetric distribution of mTORC1 and c-Myc in the first division of daughter cells of activated CD8 T cells affects the proliferation, metabolism and differentiation potential of their progeny. Asymmetric cell division occurs widely during development and other biological processes. T lymphocytes, upon activation by antigen-presenting cells, can undergo asymmetric cell division and this study provides a metabolic explanation for how that asymmetry, once established, is maintained subsequently. Katherine Verbist et al. show that asymmetric assortment of amino acid transporters leads to asymmetric distribution of the signalling complex mTORC1 and transcription factor c-Myc in the first division daughters of activated CD8 T cells. mTORC1 and c-Myc activity correlate with the proliferative potential of the resulting progeny. Asymmetric cell division, the partitioning of cellular components in response to polarizing cues during mitosis, has roles in differentiation and development1. It is important for the self-renewal of fertilized zygotes in Caenorhabditis elegans and neuroblasts in Drosophila, and in the development of mammalian nervous and digestive systems1. T lymphocytes, upon activation by antigen-presenting cells (APCs), can undergo asymmetric cell division, wherein the daughter cell proximal to the APC is more likely to differentiate into an effector-like T cell and the distal daughter is more likely to differentiate into a memory-like T cell2. Upon activation and before cell division, expression of the transcription factor c-Myc drives metabolic reprogramming, necessary for the subsequent proliferative burst3. Here we find that during the first division of an activated T cell in mice, c-Myc can sort asymmetrically. Asymmetric distribution of amino acid transporters, amino acid content, and activity of mammalian target of rapamycin complex 1 (mTORC1) is correlated with c-Myc expression, and both amino acids and mTORC1 activity sustain the differences in c-Myc expression in one daughter cell compared to the other. Asymmetric c-Myc levels in daughter T cells affect proliferation, metabolism, and differentiation, and these effects are altered by experimental manipulation of mTORC1 activity or c-Myc expression. Therefore, metabolic signalling pathways cooperate with transcription programs to maintain differential cell fates following asymmetric T-cell division.
- 11 April 2016
- Published by Springer Nature in Nature
- Vol. 532 (7599) , 389-393
Open AccessMetabolic maintenance of cell asymmetry following division in activated T lymphocytes
The asymmetric distribution of mTORC1 and c-Myc in the first division of daughter cells of activated CD8 T cells affects the proliferation, metabolism and differentiation potential of their progeny. Asymmetric cell division occurs widely during development and other biological processes. T lymphocytes, upon activation by antigen-presenting cells, can undergo asymmetric cell division and this study provides a metabolic explanation for how that asymmetry, once established, is maintained subsequently. Katherine Verbist et al. show that asymmetric assortment of amino acid transporters leads to asymmetric distribution of the signalling complex mTORC1 and transcription factor c-Myc in the first division daughters of activated CD8 T cells. mTORC1 and c-Myc activity correlate with the proliferative potential of the resulting progeny. Asymmetric cell division, the partitioning of cellular components in response to polarizing cues during mitosis, has roles in differentiation and development1. It is important for the self-renewal of fertilized zygotes in Caenorhabditis elegans and neuroblasts in Drosophila, and in the development of mammalian nervous and digestive systems1. T lymphocytes, upon activation by antigen-presenting cells (APCs), can undergo asymmetric cell division, wherein the daughter cell proximal to the APC is more likely to differentiate into an effector-like T cell and the distal daughter is more likely to differentiate into a memory-like T cell2. Upon activation and before cell division, expression of the transcription factor c-Myc drives metabolic reprogramming, necessary for the subsequent proliferative burst3. Here we find that during the first division of an activated T cell in mice, c-Myc can sort asymmetrically. Asymmetric distribution of amino acid transporters, amino acid content, and activity of mammalian target of rapamycin complex 1 (mTORC1) is correlated with c-Myc expression, and both amino acids and mTORC1 activity sustain the differences in c-Myc expression in one daughter cell compared to the other. Asymmetric c-Myc levels in daughter T cells affect proliferation, metabolism, and differentiation, and these effects are altered by experimental manipulation of mTORC1 activity or c-Myc expression. Therefore, metabolic signalling pathways cooperate with transcription programs to maintain differential cell fates following asymmetric T-cell division.
- Open Access
- 31 March 2016
- Published by American Society of Hematology in Blood
- Vol. 127 (13) , 1666-1675
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Key Points: Ruxolitinib treatment lessens immunopathology and prolongs survival in murine models of hemophagocytic lymphohistiocytosis. In vivo exposure to ruxolitinib limits CD8+ T-cell expansion and proinflammatory cytokine production.
- 31 March 2016
- Published by American Society of Hematology in Blood
- Vol. 127 (13) , 1666-1675
Open AccessJanus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Key Points: Ruxolitinib treatment lessens immunopathology and prolongs survival in murine models of hemophagocytic lymphohistiocytosis. In vivo exposure to ruxolitinib limits CD8+ T-cell expansion and proinflammatory cytokine production.
- 13 January 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (321) , 321ra7
Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1
X-linked lymphoproliferative disease (XLP-1) is an often-fatal primary immunodeficiency associated with the exuberant expansion of activated CD8+ T cells after Epstein-Barr virus (EBV) infection. XLP-1 is caused by defects in signaling lymphocytic activation molecule (SLAM)–associated protein (SAP), an adaptor protein that modulates T cell receptor (TCR)–induced signaling. SAP-deficient T cells exhibit impaired TCR restimulation-induced cell death (RICD) and diminished TCR-induced inhibition of diacylglycerol kinase α (DGKα), leading to increased diacylglycerol metabolism and decreased signaling through Ras and PKCθ (protein kinase Cθ). We show that down-regulation of DGKα activity in SAP-deficient T cells restores diacylglycerol signaling at the immune synapse and rescues RICD via induction of the proapoptotic proteins NUR77 and NOR1. Pharmacological inhibition of DGKα prevents the excessive CD8+ T cell expansion and interferon-γ production that occur in SAP-deficient mice after lymphocytic choriomeningitis virus infection without impairing lytic activity. Collectively, these data highlight DGKα as a viable therapeutic target to reverse the life-threatening EBV-associated immunopathology that occurs in XLP-1 patients.
- 13 January 2016
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 8 (321) , 321ra7
Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1
X-linked lymphoproliferative disease (XLP-1) is an often-fatal primary immunodeficiency associated with the exuberant expansion of activated CD8+ T cells after Epstein-Barr virus (EBV) infection. XLP-1 is caused by defects in signaling lymphocytic activation molecule (SLAM)–associated protein (SAP), an adaptor protein that modulates T cell receptor (TCR)–induced signaling. SAP-deficient T cells exhibit impaired TCR restimulation-induced cell death (RICD) and diminished TCR-induced inhibition of diacylglycerol kinase α (DGKα), leading to increased diacylglycerol metabolism and decreased signaling through Ras and PKCθ (protein kinase Cθ). We show that down-regulation of DGKα activity in SAP-deficient T cells restores diacylglycerol signaling at the immune synapse and rescues RICD via induction of the proapoptotic proteins NUR77 and NOR1. Pharmacological inhibition of DGKα prevents the excessive CD8+ T cell expansion and interferon-γ production that occur in SAP-deficient mice after lymphocytic choriomeningitis virus infection without impairing lytic activity. Collectively, these data highlight DGKα as a viable therapeutic target to reverse the life-threatening EBV-associated immunopathology that occurs in XLP-1 patients.
- 1 June 2013
- Published by Elsevier in Cell Metabolism
- Vol. 17 (6) , 895-900
The Relationship between Metabolism and the Autophagy Machinery during the Innate Immune Response
- 1 June 2013
- Published by Elsevier in Cell Metabolism
- Vol. 17 (6) , 895-900
The Relationship between Metabolism and the Autophagy Machinery during the Innate Immune Response
- 1 December 2012
- Published by Elsevier in Seminars in Immunology
- Vol. 24 (6) , 399-404
T cell metabolism and the immune response
- 1 December 2012
- Published by Elsevier in Seminars in Immunology
- Vol. 24 (6) , 399-404
T cell metabolism and the immune response